• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » MDUFMA: FDA proposes user fee changes

MDUFMA: FDA proposes user fee changes

October 11, 2011 By MassDevice staff

MDUFMA

Minutes from a meeting between representatives from the medical device and diagnostics industry and the Food & Drug Administration reveal a raft of proposed changes to the way the federal watchdog agency reviews the products.

The August meeting, held as part of the seemingly never-ending wrangling between industry and the FDA, involved a baker’s dozen representatives of the agency and 11 people from various industry groups and firms, including Abbott (NYSE:ABT), Boston Scientific (NYSE:BSX), Medtronic (NYSE:MDT), Philips (NYSE:PHG) and LabCorp (NYSE:LH).

“The agency indicated its goal of achieving several objectives that are held in common with industry: Predictability of submission requirements, improved quality of submissions, transparency during the review of submissions, predictability of decision timelines, consistency of review practices, and an adequately resourced premarket program,” according to the minutes of the meeting. “The agency proposal incorporates total time goals in response to Industry’s July 26 proposal. The agency indicated that there are significant concerns about this approach within the agency and within the larger stakeholder community, but expressed FDA’s willingness to work towards an acceptable approach for total time goals because this particular element is important to Industry.”

Sign up to get our free newsletters delivered straight to your inbox

The FDA’s performance goal proposal include:

  • “A defined total time goal for each submission type, with a portion of that time allotted to the agency for review of the submission and a portion allotted to the applicant to respond to feedback from the agency.”
  • Milestones for interactions with applicants to “allow the applicant to have a clear understanding of their submission status and the likely timing of a marketing decision.”
  • Process improvements, for example “a structured pre-submission process.”
  • An annual “Product Development Fee” triggered by “pre-submission” or investigational device exemption applications.
    • Pre-Submissions: Goals for scheduling a meeting or teleconference within 60 days of receipt of a complete pre-submission package.
    • Initial feedback prior to the meeting and meeting minutes finalized within a set time after the meeting.
    • A commitment to certain number of meetings and teleconferences per year.
    • Additional meetings honored and “scheduled as quickly as resources permit, and hopefully in the specified timelines” but not subject to the goals.
    • The goals would only apply to the first pre-submission meeting request for a specific device. “Subsequent meetings for the same device would not be subject to the goals, although the agency would strive to meet the same timelines.”
    • A guidance document regarding pre-submissions, “including criteria for handling situations where the agency’s thinking has changed since the advice given during a pre-submission meeting.”
  • Submission Performance Goals: A single high-percentage goal for each performance metric. The proposal included a similar structure for each submission type:
    1. A planned “Initial Interaction” to “communicate the name of the reviewer and the acceptance of the submission for further review after an assessment against objective acceptance criteria.”
    2. A “Substantive Interaction” to “communicate with the applicant at the point when the reviewer has completed a substantive review of the submission (this could be a formal deficiency letter, a “telephone hold,” or a status email explaining that no hold is needed).”
    3. “Interactive Review” immediately following the substantive interaction if no hold is required or following receipt of a response to questions posed in the Substantive Interaction if a hold is required.
    4. A “Total Time goal” in which a marketing decision would be provided to the applicant. “The Total Time structure would allot a specific number of days to the Agency for an initial internal review and Interactive Review with the applicant, and a specific number of days for industry to respond to questions posed in a Substantive Interaction when a hold was required. … If the Agency does not complete our review within the allotted days, the goal would be considered not to be met for that submission. If the applicant does not respond within their allotted days following a hold, their submission would be considered withdrawn.”
  • “The Agency’s proposal includes all 510(k)s for which a fee was paid in goal performance reporting, regardless of the final decision.
  • A high percentage metric for each cohort with quarterly reports to “highlight submissions that missed goals, reporting on the total number of elapsed days for each open submission each quarter” until the submission is complete.
  • Performance goals for CLIA Waiver applications “with goals designed to be achievable without the application of additional resources in order to remain consistent with the CLIA statute.”
  • An increase in time of 25 percent for each of the outlined goals for combination product submissions and companion diagnostic submissions, applied both to agency time and the applicant’s time.
  • The performance goals would only apply for annual cohorts with more than 10 submissions of each type.
  • Process Improvements : Deploy user fee revenue “to enhance scientific review capacity, reduce the ratio of review staff to supervisors, conduct additional training, and develop targeted retention bonuses to address attrition of review staff.”
  • Apply user fee revenue to management training and review staff training, “including a MDUFA III training program and a reviewer certification program, including publishing the curriculum of the certification program and accepting comments from stakeholders.”
  • Two “Vendor Days” a year
  • Reauthorize the third party review program.
  • An independent assessment of review process management to be conducted by a private, independent consulting firm.
  • A guidance document outlining objective criteria for revised “refuse to accept/refuse to file” checklists.
  • More detailed performance reporting, “increasing the granularity of the data per Industry’s request.”
  • Deploy user fee revenue to improve the guidance document process, “including increasing resources dedicated to the process and posting a list of prioritized guidance documents for stakeholder comment.”
  • A transition period in order to allow for successful implementation including increasing staffing, training, and putting new systems in place.

Filed Under: Food & Drug Administration (FDA), News Well Tagged With: Abbott, Boston Scientific, Laboratory Corp. of America Holdings, MDUFMA, Philips

In case you missed it

  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • NuVasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance
  • Surgalign settles on OEM business sale, posts Q2 earnings miss
  • Alcon lowers its 2022 forecast amid strong dollar
  • Masimo beats Street in Q2 as healthcare business catches up
  • Senseonics stock is up as it sticks by revenue guidance
  • Butterfly Network asks judge to dismiss Fujifilm Sonosite IP suit
  • Stereotaxis stock down amid cloudy outlook
  • BD, Labcorp collaborate on flow cytometry-based diagnostics
  • NeuroOne submits special FDA 510(k) application for Evo sEEG electrode

RSS From Medical Design & Outsourcing

  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy